Abstract:AbstractThe transcription factor NRF2 (NFE2L2) is a pivotal activator of genes encoding cytoprotective and detoxifying enzymes that limit the action of cytotoxic therapies in cancer. NRF2 acts by binding antioxidant response elements (ARE) in its target genes, but there is relatively limited knowledge about how it is negatively controlled. Here, we report that retinoic X receptor alpha (RXRα) is a hitherto unrecognized repressor of NRF2. RNAi-mediated knockdown of RXRα increased basal ARE-driven gene expression and induction of ARE-driven genes by the NRF2 activator tert-butylhydroquinone (tBHQ). Conversely, overexpression of RXRα decreased ARE-driven gene expression. Biochemical investigations showed that RXRα interacts physically with NRF2 in cancer cells and in murine small intestine and liver tissues. Furthermore, RXRα bound to ARE sequences in the promoters of NRF2-regulated genes. RXRα loading onto AREs was concomitant with the presence of NRF2, supporting the hypothesis that a direct interaction between the two proteins on gene promoters accounts for the antagonism of ARE-driven gene expression. Mutation analyses revealed that interaction between the two transcription factors involves the DNA-binding domain of RXRα and a region comprising amino acids 209-316 in human NRF2 that had not been defined functionally, but that we now designate as the NRF2-ECH homology (Neh) 7 domain. In non–small cell lung cancer cells where NRF2 levels are elevated, RXRα expression downregulated NRF2 and sensitized cells to the cytotoxic effects of therapeutic drugs. In summary, our findings show that RXRα diminishes cytoprotection by NRF2 by binding directly to the newly defined Neh7 domain in NRF2. Cancer Res; 73(10); 3097–108. ©2013 AACR.

Regulation of the Nongenomic Actions of Retinoid X Receptor-Α by Targeting the Coregulator-Binding Sites

Rexinoid Inhibits Nrf2-Mediated Transcription Through Retinoid X Receptor Alpha

Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor

Targeting Truncated RXRα for Cancer Therapy.

Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor

RXR Signaling Targeted Cancer Therapy

Overview of the Structure-Based Non-Genomic Effects of the Nuclear Receptor RXRα

The Pathophysiological Roles and Regulatory Mechanism of Retinoic Acid Receptor-related Orphan Receptors

Bexarotene: a Promising Anticancer Agent

Structural Basis for Retinoic X Receptor Repression on the Tetramer

Therapeutic modulation of retinoid X receptors – SAR and therapeutic potential of RXR ligands and recent patents

The Function of Retinoid X Receptor Α in Cancer Cells

RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2.

Identification of a New RXRα Antagonist Targeting the Coregulator-Binding Site.

A review of the molecular design and biological activities of RXR agonists

Retinoid X Receptor Regulates Nur77/Thyroid Hormone Receptor 3-Dependent Apoptosis by Modulating Its Nuclear Export and Mitochondrial Targeting

Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation

Retinoid X Receptor Regulates Nur77/TR3-Dependent Apoptosis by Modulating Its Nuclear Export and Mitochondrial Targeting

Retinoid X receptor ligands: a patent review (2007 – 2013)

Retinoid X Receptor Heterodimers in Hepatic Function: Structural Insights and Therapeutic Potential

Nitrostyrene Derivatives Act as RXRα Ligands to Inhibit TNFα Activation of NF-κB.